Review
Immunology
Yang Zhao, Junfeng Du, Xiaofei Shen
Summary: Myeloid-derived suppressor cells (MDSCs) are a major negative regulator in tumor microenvironment (TME) by inhibiting immune response and promoting immunosuppression. This review focuses on the features of MDSCs in TME and potential targets for tumor immunotherapy. Therapies aiming to reprogram TME, prevent MDSC immunosuppression, promote MDSC differentiation, and impact MDSC recruitment and abundance in tumor site are discussed. Combinatorial strategies to improve clinical efficacy and outcomes of cancer patients through better understanding of MDSCs generation and suppression in TME are also summarized.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Xidan Gao, Hongshu Sui, Shang Zhao, Xingmei Gao, Yanping Su, Peng Qu
Summary: MDSCs, a heterogeneous population of immature myeloid cells accumulating in tumor-bearing hosts, play a critical role in promoting tumor immune escape. Therapeutic strategies targeting MDSCs have shown potential in enhancing the efficacy of tumor immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Hui Zhang, Qi-Wei Li, Yuan-Yuan Li, Xue Tang, Ling Gu, Han-Min Liu
Summary: Pulmonary hypertension (PH) is characterized by increased pulmonary vascular resistance and pressure, and the relationship between myeloid-derived suppressor cells (MDSCs) and PH has been studied. MDSCs are a group of cells that can suppress T-cell responses and potentially exacerbate the development of diseases. Understanding the relationship between MDSCs and PH can help identify potential therapeutic targets for the treatment of PH.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Ching-Chuan Hsieh, Cheng-Chih Chang, Yung-Chien Hsu, Chun-Liang Lin
Summary: In the development of diabetic kidney disease, the dysregulation of glomerular cell types is crucial, and MDSCs exhibit anti-inflammatory activities that help improve renal fibrosis in diabetic mice.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Cell Biology
Tianmiao Ma, Bernhard W. Renz, Matthias Ilmer, Dominik Koch, Yuhui Yang, Jens Werner, Alexandr V. Bazhin
Summary: Myeloid-derived suppressor cells (MDSCs) play a crucial role in the tumor microenvironment (TME) and have been linked to poor prognosis and drug resistance in cancer. Further research is needed to fully understand the definition and phenotypes of MDSCs in humans.
Review
Chemistry, Multidisciplinary
Xinghang Dai, Long Ren, Mengxi Liu, Hao Cai, Hu Zhang, Qiyong Gong, Zhongwei Gu, Kui Luo
Summary: MDSCs have been explored as an important immunotherapeutic target in cancer immunology, and nanomedicines have shown potential in reversing immunosuppressive tumors into immunoresponsive ones to enhance therapeutic efficacy.
Article
Medicine, General & Internal
Wei-Li Xu, Bao-Jun Shi, Suo-Lin Li, Feng-Xue Yu, Li-Na Guo, Meng Li, Zhi-Gang Hu, Gui-Xin Li, Hui Zhou
Summary: The study demonstrated that low-dose doxorubicin can enhance the efficacy of immunotherapy in neuroblastoma by selectively inhibiting MDSCs, promoting immune function, and inhibiting tumor growth.
CHINESE MEDICAL JOURNAL
(2021)
Article
Oncology
Yu Chen, Yanquan Xu, Huakan Zhao, Yu Zhou, Jiangang Zhang, Juan Lei, Lei Wu, Mingyue Zhou, Jingchun Wang, Shuai Yang, Xiao Zhang, Guifang Yan, Yongsheng Li
Summary: Cancer immunotherapy targeting myeloid-derived suppressor cells (MDSCs) is a promising anti-cancer strategy. This study explored the regulatory mechanisms of cholesterol metabolic reprogramming in MDSCs and found that cholesterol deficiency increased the immunosuppressive activity of MDSCs. Mechanistically, cholesterol elimination induced nuclear accumulation of LXR beta and enhanced the binding of LXR beta-RXR alpha on Arg1 promoter. Furthermore, itraconazole improved MDSC immunosuppressive activity and promoted tumor growth by inhibiting the RIPK3-AKT-mTORC1 pathway and impeding cholesterol synthesis.
Review
Gastroenterology & Hepatology
Samantha B. Kemp, Marina Pasca di Magliano, Howard C. Crawford
Summary: Pancreatic ductal adenocarcinoma (PDA) is a nearly universally lethal malignancy characterized by extensive infiltration of immunosuppressive myeloid cells, inhibiting normal immune functions and promoting carcinogenesis. Current immune checkpoint therapy has not been effective in PDA, highlighting the importance of understanding the mechanisms underlying immune suppression in this type of cancer.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Sabina Kaczanowska, Daniel W. Beury, Vishaka Gopalan, Arielle K. Tycko, Haiying Qin, Miranda E. Clements, Justin Drake, Chiadika Nwanze, Meera Murgai, Zachary Rae, Wei Ju, Katherine A. Alexander, Jessica Kline, Cristina F. Contreras, Kristin M. Wessel, Shil Patel, Sridhar Hannenhalli, Michael C. Kelly, Rosandra N. Kaplan
Summary: By utilizing genetically engineered myeloid cells to deliver IL-12, immune suppression in the premetastatic niche can be reversed, resulting in improved survival and reduced metastatic and primary tumor burden in tumor-bearing mice.
Review
Biochemistry & Molecular Biology
Maria Luisa Sanchez-Leon, Carlos Jimenez-Cortegana, Silvia Silva Romeiro, Carmen Garnacho, Luis de la Cruz-Merino, Daniel J. Garcia-Dominguez, Lourdes Hontecillas-Prieto, Victor Sanchez-Margalet
Summary: Breast cancer is the most diagnosed tumor in women with diverse molecular profiles. Despite the advancements in early detection and therapy, patients with metastatic disease have low survival rates. Immunotherapy, due to its ability to modulate the immune system, has emerged as a promising alternative. This review focuses on the new immunotherapies in breast cancer in the last five years and discusses the role of myeloid-derived suppressor cells as a therapeutic target.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Immunology
Fabio Magalhaes-Gama, Fabiola Silva Alves-Hanna, Nilberto Dias Araujo, Mateus Souza Barros, Flavio Souza Silva, Claudio Lucas Santos Catao, Julia Santos Moraes, Izabela Cabral Freitas, Andrea Monteiro Tarrago, Adriana Malheiro, Andrea Teixeira-Carvalho, Allyson Guimaraes Costa
Summary: The leukemic microenvironment contains diverse immune cells, including myeloid cells, that play important roles in regulating immune responses. The activation of different myeloid cell populations can have implications for immunosuppression, survival, metastasis, and tumor surveillance. Myeloid cell subpopulations have potential as predictive biomarkers and therapeutic targets in leukemia treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Pharmacology & Pharmacy
Shweta Joshi, Andrew Sharabi
Summary: This review discusses the role of MDSCs in tumor growth, their interaction with NK cells, and the impact on NK cell-based immunotherapies, presenting strategies to enhance NK cell cytotoxicity.
PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Oncology
Yijun Wang, Tongyue Zhang, Mengyu Sun, Xiaoyu Ji, Meng Xie, Wenjie Huang, Limin Xia
Summary: Myeloid-derived suppressor cells (MDSCs) hinder T cell infiltration into tumor sites, restricting the effectiveness of immune checkpoint inhibitors for certain patients, while targeting MDSCs has shown potent inhibitory effects in multiple tumors, including hepatocellular carcinoma. Clinically, the frequency of MDSCs is closely linked to the prognosis and predictive biomarkers of HCC patients, as well as the effectiveness of immune checkpoint inhibitors and tyrosine kinase inhibitors.
Review
Medicine, Research & Experimental
Anik Pramanik, Sankar Bhattacharyya
Summary: The MDSC population in the tumor microenvironment plays a crucial role in tumor immune evasion and cancer progression by disrupting antitumor T cell activity and potentially affecting other immune cell functions.